

T F W



Atty Dkt No. 01-0157-CIP
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Elzein, et al.

Serial No.: 10/722,702

Filing Date: 25-Nov-2003

Title: Adenosine Receptor A3 Agonists

Confirmation No.: Not Assigned

Group Art Unit: 1623

Examiner: Not Assigned

INFORMATION DISCLOSURE STATEMENT

Mail Stop IDS
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. Applicants respectfully request that the Examiner review and make of record the references identified below.

The references identified below were disclosed and/or cited in parent application Serial No. 10/212,896, filed August 5, 2002. As such, copies of the references are not included pursuant to the provisions of 37 CFR § 1.98(d).

A PTO-1449 form listing the references accompanies this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record. The references are as follows:

FOREIGN PATENT DOCUMENTS

Document No.	Publication Date	Country
WO 00/78777	December 28, 2000	PCT
WO 00/78778	December 28, 2000	PCT
WO 00/78779	December 28, 2000	PCT

NONPATENT DOCUMENTS

KLOTZ et al: "2-Substituted N-Ethylcarboxamidoadenosine Derivatives as High-Affinity Agonists at Human A3 Adenosine Receptors", Nauny-Schmiedeberg's Archives of Pharmacology, Springer, Berlin, DE., Vol. 360, no. 2, 1999, pages 103-108 XP000984051, ISSN: 0028-1298, compound 8, tables 1,2



Atty Dkt No. 01-0157-CIP
Serial No. 10/722,702

NONPATENT DOCUMENTS

BARALDI et al: "Novel N6-(Substituted-phenylcarbamoyl) Adenosine-5'-Uronamides as Potent Agonist for A2 Adenosine Receptors", Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 39, no. 3, February 1996 (1996-02), pages 802-806, XP002913657, ISSN: 0022-2623, conclusions on page 804, pages 803, column 2, paragraph 4


As the subject application was filed after June 30, 2003, copies of the U.S. patents and/or publications disclosed in this Information Disclosure Statement are not required and, therefore, are not included.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any of the above references constitutes prior art to the present application within the meaning of 35 USC § 102.

As applicants have not yet received a first Action on the merits, no fee is required for filing this Information Disclosure Statement. If, however, the PTO finds that for some reason a fee is found to be necessary, our Deposit Account No. 50-1789 may be charged therefor.

Respectfully submitted,

By:


J. Elin Hartrum
Registration No. 43,663

CV Therapeutics, Inc.
3172 Porter Drive
Palo Alto, California 94304
Telephone: (650) 384-8755
Facsimile: (650) 475-0359

S:\LEGALCVT\Patent\Docs\01-157\01-157-CIP\IDS.DOC

AUG 16 2004

5C32

Substitute for Form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	01-0157-CIP
-------	---	----	---	------------------------	-------------

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Document No.	Issue Date or Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document No.	Publication Date	Country	Class	Subclass	T
		WO 00/78777	December 28, 2000	PCT			
		WO 00/78778	December 28, 2000	PCT			
		WO 00/78779	December 28, 2000	PCT			

OTHER DOCUMENTS — NONPATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), Title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T
		KLOTZ et al: "2-Substituted N-Ethylcarboxamidoadenosine Derivatives as High-Affinity Agonists at Human A3 Adenosine Receptors", Nauny-Schmiedeberg's Archives of Pharmacology, Springer, Berlin, DE., Vol. 360, no. 2, 1999, pages 103-108 XP000984051, ISSN: 0028-1298, compound 8, tables 1,2					
		BARALDI et al: "Novel N6-(Substituted-phenylcarbamoyl) Adenosine-5'-Uronamides as Potent Agonist for A2 Adenosine Receptors", Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 39, no. 3, February 1996 (1996-02), pages 802-806, XP002913657, ISSN: 0022-2623, conclusions on page 804, pages 803, column 2, paragraph 4					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.